logo

Stock Screener

Forex Screener

Crypto Screener

CFB

CrossFirst Bankshares, Inc. (CFB)

$

15.99


Key metrics

Financial statements

Free cash flow per share

Free cash flow per share

1.9084

Market cap

Market cap

788.5 Million

Price to sales ratio

Price to sales ratio

1.7816

Debt to equity

Debt to equity

0.1099

Current ratio

Current ratio

0.2581

Income quality

Income quality

1.3337

Average inventory

Average inventory

105.4 Million

ROE

ROE

0.1015



Technology

Technology

Technology – consumer electronics

Largecap

Largecap

With a market cap of 121,78 bil stock is ranked 1

Low risk

Low risk

ISS score of this stock is ranked 1


Company description

Profile

CrossFirst Bankshares, Inc. operates as the bank holding company for CrossFirst Bank, offering a wide array of banking and financial services tailored for businesses, business owners, and professionals, as well as their personal networks. The company provides diverse loan options, including commercial real estate, construction and development, 1-4 family real estate, commercial, energy, and consumer loans. Additionally, CrossFirst Bankshares caters to its clients through a variety of deposit products, which encompass noninterest-bearing demand and interest-bearing deposits, such as transaction accounts, savings accounts, money market accounts, and certificates of deposit. Their offerings extend to personal and business checking and savings accounts, negotiable order of withdrawal accounts, and brokered and reciprocal deposits. Furthermore, the company supplies international banking services, treasury management services, automated teller machine access, and mobile banking services, showcasing its commitment to comprehensive financial solutions. The EBITDA is $93,570,000.00 a key indicator of the company's operational profitability, while the income before tax ratio is $0.36 reflecting the pre-tax margin. Additionally, the EBITDA ratio is $0.41 highlighting the company's operational efficiency. The company reported selling, general, and administrative expenses of $99,325,000.00 indicating its operational overhead costs, and the net total of other income and expenses is $0.00 reflecting non-core financial activities. As of December 31, 2021, it had nine full-service banking offices across Kansas, Missouri, Oklahoma, Arizona, and Texas. Founded in 2007 and headquartered in Leawood, Kansas, CrossFirst Bankshares is a notable entity in the financial sector. The stock is affordable at $15.99 making it suitable for budget-conscious investors. With a low average trading volume of 236,111.00 the stock indicates lower market activity, which may reflect investor interest levels. Moreover, with a market capitalization of $788,642,790.00 the company is classified as a small-cap player in the financial landscape. It is a key player in the Banks - Regional industry, contributing significantly to the overall market landscape. Additionally, it belongs to the Financial Services sector, driving innovation and growth within its parameters.

What is CrossFirst Bankshares, Inc. (CFB)'s current stock price?

The current stock price of CrossFirst Bankshares, Inc. (CFB) is $15.99 as of 2025-02-28. Prices may fluctuate during the trading day. For real-time updates, check your brokerage platform or financial news websites.

Analysts predict CrossFirst Bankshares, Inc. stock to fluctuate between $10.64 (low) and $19.22 (high) in the next 365 days, reflecting market expectations and potential volatility.

As of 2025-02-28, CrossFirst Bankshares, Inc.'s market cap is $788,642,790, based on 49,321,000 outstanding shares.

Compared to Meta Platforms, Inc. Class A Common Stock, CrossFirst Bankshares, Inc. has a Lower Market-Cap, indicating a difference in performance.

To buy CrossFirst Bankshares, Inc. (CFB) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CFB. Place an order (Market, Limit, etc.).

The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.

Revenue: $231,016,000 | EPS: $1.35 | Growth: 8.87%.

Visit https://www.crossfirstbank.com/investor-relations for detailed financial reports.

You can explore historical data from here

All-time high: $19.22 (2024-07-31) | All-time low: $5.66 (2020-03-16).

Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.


News

CFB

globenewswire.com

a month ago

First Busey Corporation Announces 2025 First Quarter Results

LEAWOOD, Kan., April 22, 2025 (GLOBE NEWSWIRE) -- First Busey Corporation (Nasdaq: BUSE) reports first quarter results.

CFB

zacks.com

4 months ago

CrossFirst (CFB) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for CrossFirst (CFB) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

CFB

zacks.com

4 months ago

CrossFirst Bankshares (CFB) Surpasses Q4 Earnings and Revenue Estimates

CrossFirst Bankshares (CFB) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.39 per share a year ago.

CFB

globenewswire.com

4 months ago

CrossFirst Bankshares, Inc. Reports Record Fourth Quarter and Record Full Year 2024 Results

LEAWOOD, Kan., Jan. 28, 2025 (GLOBE NEWSWIRE) -- CrossFirst Bankshares, Inc. (Nasdaq: CFB), the bank holding company for CrossFirst Bank, today reported operating results for the fourth quarter and full-year ended December 31, 2024.

CFB

businesswire.com

6 months ago

Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company's investigational RNA interference (RNAi) therapeutic targeting complement factor B being developed as a potential treatment for complement mediated diseases. The data were presented today, December 11, 2024, at the 8th Complement-Based Drug Development Summit being held in Boston. “Dysregulated activation of the complement sy.

CFB

businesswire.com

6 months ago

CROSSFIRST BANKSHARES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CrossFirst Bankshares, Inc. - CFB

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of CrossFirst Bankshares, Inc. (NasdaqGS: CFB) to First Busey Corporation (NasdaqGS: BUSE). Under the terms of the proposed transaction, shareholders of CrossFirst will receive 0.6675 shares of First Busey common stock for each share of CrossFirst that they own. KSF is seeking to determine whether this considerat.

CFB

zacks.com

7 months ago

CrossFirst (CFB) Upgraded to Strong Buy: What Does It Mean for the Stock?

CrossFirst (CFB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

See all news

logo
Stocks, Indicators, Pattern screeners all at one place
Stock Screener
Forex Screener
Crypto Screener